Literature DB >> 1331236

Characterization of the Mlsf system. II. Identification of mouse mammary tumor virus proviruses involved in the clonal deletion of self-Mlsf-reactive T cells.

M Foo-Phillips1, C A Kozak, M A Principato, R Abe.   

Abstract

The genetic linkage of loci encoding stimulatory Mlsa and Mlsc determinants with proviruses of mouse mammary tumour viruses (MMTV) has been shown. We previously have reported that the ligand(s) for V beta 5, V beta 11, and V beta 12 behaves as a novel minor lymphocyte-stimulating (Mls) determinant(s), Mlsf, to induce the strong proliferation of unprimed T cells, and that this ligand(s) also functions as a self-Ag for the clonal deletion of self-reactive T cells. In the accompanying paper (Part I), a unique polymorphism characteristic of the Mlsf gene product is presented. In order to determine the genetic basis for this novel Mls system, we examined the progeny of multiple genetic crosses to identify the MMTV proviral loci involved in the clonal deletion of self-Mlsf-reactive T cells. Results from these investigations indicated that at least three known MMTV proviruses, Mtv-8, Mtv-9, and Mtv-11 are involved in the expression of Mlsf gene products. Presence of Mtv-9 results in the complete deletion of V beta 5, V beta 11, and V beta 12; Mtv-8 is associated with the complete deletion of V beta 12, but only a partial deletion of V beta 11 (primarily CD4-positive T cell subset) with little or no deletion of V beta 5; and Mtv-11 induces the complete deletion of V beta 11 and V beta 12, but no deletion of V beta 5. Given the significant sequence homology in the C-terminal portion of the open reading frame (ORF) region among these three MMTV and the almost equivalent effect of these three MMTV provirus upon the V beta 12 repertoire, their apparent hierarchic effect upon the V beta 5 and V beta 11 repertoires suggests that affinity differences in recognition of the same determinant by different TCR V beta may play a significant role in the clonal deletion of self-reactive T cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331236

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Complete Nucleotide Sequence of Mouse Mammary Tumor Virus from JYG Chinese Wild Mice: Absence of Bacterial Insertion Sequences in the Cloned Viral gag Gene.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

2.  TCR revision generates functional CD4+ T cells.

Authors:  J Scott Hale; Maramawit Wubeshet; Pamela J Fink
Journal:  J Immunol       Date:  2010-10-22       Impact factor: 5.422

3.  Serum antibodies to HIV-1 are produced post-measles virus infection: evidence for cross-reactivity with HLA.

Authors:  P V Baskar; G D Collins; B A Dorsey-Cooper; R S Pyle; J E Nagel; D Dwyer; G Dunston; C E Johnson; N Kendig; E Israel; D R Nalin; W H Adler
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

4.  Expression of mouse mammary tumor virus superantigen mRNA in the thymus correlates with kinetics of self-reactive T-cell loss.

Authors:  A Barnett; F Mustafa; T J Wrona; M Lozano; J P Dudley
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  Contrasting effects from a single major histocompatibility complex class II molecule (H-2E) in recovery from Friend virus leukemia.

Authors:  L L Perry; M Miyazawa; K Hasenkrug; K Wehrly; C S David; B Chesebro
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

6.  Susceptibility to tumors induced by polyoma virus is conferred by an endogenous mouse mammary tumor virus superantigen.

Authors:  A E Lukacher; Y Ma; J P Carroll; S R Abromson-Leeman; J C Laning; M E Dorf; T L Benjamin
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

7.  The use of mammary tumor virus (Mtv)-negative and single-Mtv mice to evaluate the effects of endogenous viral superantigens on the T cell repertoire.

Authors:  M T Scherer; L Ignatowicz; A Pullen; J Kappler; P Marrack
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.